ArriVent BioPharma
AVBP
80 hedge funds and large institutions have $757M invested in ArriVent BioPharma in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 11 reducing their positions, and 11 closing their positions.
209% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 11
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
24% more capital invested
Capital invested by funds: $612M → $757M (+$145M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
18% more funds holding
Funds holding: 68 → 80 (+12)
7.33% more ownership
Funds ownership: 77.13% → 84.47% (+7.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$11.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.68M |
| 3 |
BlackRock
New York
|
+$5.85M |
| 4 |
HLAM
Hidden Lake Asset Management
New York
|
+$5.3M |
| 5 |
Goldman Sachs
New York
|
+$3.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$9.75M |
| 2 |
Millennium Management
New York
|
-$4.71M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2M |
| 4 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$1.18M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$1.11M |
AVBP Hedge Fund Activity: Q4 2024 in Review
80 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q4 2024, worth a combined $757M — up 24% from $612M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AVBP positions and 11 closed out — a net gain of 13 holders — while 34 added to existing stakes and 11 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $11.5M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $9.75M sold.
- 80 institutional investors held ArriVent BioPharma (AVBP) as of Q4 2024, up from 68 in Q3 2024.
- Funds reported $757M of ArriVent BioPharma stock for Q4 2024, up 24% quarter-over-quarter.
- 24 funds opened new ArriVent BioPharma positions in Q4 2024 and 11 closed out, a net change of +13 holders.
- The largest ArriVent BioPharma buyer in Q4 2024 was Suvretta Capital Management, an estimated $11.5M added.
- The largest ArriVent BioPharma seller in Q4 2024 was Perceptive Advisors, an estimated $9.75M sold.
Based on aggregated 13F filings for Q4 2024.